COTA, Inc., an oncology real-world data and analytics company, announced insights from a study of practicing oncologists that reveals 83 percent of oncologists surveyed believe real-world data is critical to accelerating the development of potentially life-saving cancer drugs and treatments. The study, which was conducted by independent research firm PureSpectrum and COTA, analyzed 200 practicing oncologists’ perceptions on a number of issues related to cancer research and clinical trials, including: diversity, the use of real-world data (RWD), and the effect that the lightning-quick COVID-19 vaccine development process had on patient expectations.
